Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Zuberbier T et al. – For patients who do not respond to a four–fold increase in dosage of nonsedating H1–antihistamines, it is recommended that second–line therapies should be added to the antihistamine treatment. In the choice of second–line treatment, both their costs and risk/benefit profiles are most important to consider. Corticosteroids are not recommended for long–term treatment due to their unavoidable severe adverse effects.


Today in Derm Allergy/Immunology...keeping you current

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

Solar urticaria
Allergy and Asthma Proceedings, 10/12/09

The definition and diagnostic testing of physical and cholinergic urticarias - EAACI/GA2LEN/EDF/UNEV consensus panel recommendations
Allergy, 11/16/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address